Doctors say the latest Phase
III data for pertuzumab should cement its place as standard of care for
first-line metastatic breast cancer, but they are even more excited about
upcoming data for the mAb in adjuvant patients, which could establish its
ability to prevent progression in the first place.
This month, Roche
and its Genentech
Inc. unit presented detailed results from the double-blind,
international Phase III CLEOPATRA trial of pertuzumab in first-line metastatic
breast cancer. The companies had reported in July that pertuzumab met the
primary endpoint of progression-free survival (PFS).